<DOC>
	<DOCNO>NCT00976729</DOCNO>
	<brief_summary>This first time NOX-E36 administer man . The principal aim study obtain safety tolerability data NOX-E36 administer single intravenous ( IV ) subcutaneous ( SC ) dose healthy male female subject . This information , together pharmacokinetic pharmacodynamic data , help establish dos , dosage regimen route administration suitable multiple dose administration healthy volunteer , follow study patient population .</brief_summary>
	<brief_title>NOX-E36 First-in-Human ( FIH ) Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Healthy male female subject Body mass index ( BMI ) 19.0 29.0 kg/m2 inclusive Body weight 50 100 kg inclusive Creatinine clearance great 80 mL/min Male female subject whose partner willing use appropriate contraception method Intake prescribe systemic topical medication within 14 day prior dose Intake nonprescribed systemic topical medication ( include herbal remedy ) within 7 day prior dose ( exception vitamin/mineral supplement ) Supine blood pressure supine pulse rate high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 40 bpm , respectively , confirm repeat assessment History clinically significant neurological , dermatological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological major disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>monocyte chemoattractant protein-1 ( MCP-1 )</keyword>
	<keyword>L-oligonucleotide aptamer</keyword>
	<keyword>Spiegelmer</keyword>
</DOC>